ArticleNeurology(R) neuroimmunology & neuroinflammation2020
CSF chitinase 3-like-1 association with disability of primary progressive MS.
Open access · goldAbstract read
In one paragraph
Article in Neurology(R) neuroimmunology & neuroinflammation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Clinical and Paraclinical Biomarkers and the Hitches to Assess Conversion to Secondary Progressive Multiple Sclerosis: A Systematic Review.Frontiers in neurology · 2021Pooled it
- Plasma CHI3L1 as a marker of cognitive and structural brain changes in radiologically isolated syndrome.BMJ neurology open · 2026Article
- Profiling the Cerebrospinal Fluid Proteome in Progressive Multiple Sclerosis: Treatment Effects and Associations with IgM Oligoclonal Bands.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025Article
- No Relation Between Cognitive Impairment, Physical Disability and Serum Biomarkers in a Cohort of Progressive Multiple Sclerosis Patients.Biomolecules · 2025Article
- Brain-derived blood biomarkers in multiple sclerosis-current trends and beyond.Frontiers in immunology · 2025Review
- Impact of preanalytical factors on blood CHI3L1 levels.Frontiers in immunology · 2025Article
- Review
- Glial Cells as Key Regulators in Neuroinflammatory Mechanisms Associated with Multiple Sclerosis.International journal of molecular sciences · 2024Review
- Primary Progressive Multiple Sclerosis-A Key to Understanding and Managing Disease Progression.International journal of molecular sciences · 2024Review
- Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort.Journal of neurology · 2024Observational
- The Peripheral Profile of the Chitinase 3-like-1 in Benign Multiple Sclerosis - A Single Centre's Experience.CNS & neurological disorders drug targets · 2024Observational
- How Early Is Early Multiple Sclerosis?Journal of clinical medicine · 2023Review
- Chitinase-3-like 1-protein in CSF: a novel biomarker for progression in patients with multiple sclerosis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Article
- The Heterogeneous Multiple Sclerosis Lesion: How Can We Assess and Modify a Degenerating Lesion?International journal of molecular sciences · 2023Review
- CSF CXCL13 and Chitinase 3-like-1 Levels Predict Disease Course in Relapsing Multiple Sclerosis.Molecular neurobiology · 2023Article
- Novel CSF Biomarkers Tracking Autoimmune Inflammatory and Neurodegenerative Aspects of CNS Diseases.Diagnostics (Basel, Switzerland) · 2022Review
- The role of glial cells in multiple sclerosis disease progression.Nature reviews. Neurology · 2022Review
- Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations.International journal of molecular sciences · 2022Review
- A causal relationship between leukocyte telomere length and multiple sclerosis: A Mendelian randomization study.Frontiers in immunology · 2022Article
- Biological Markers in Early Multiple Sclerosis: the Paved Way for Radiologically Isolated Syndrome.Frontiers in immunology · 2022Review
Corrections and comments
- Commented on by
Authors and funding
13 authors at 1 institution in 1 country.
Francisco Pérez-MirallesFrom the Neuroimmunology Unit-National Referral Center for Demyelinating Diseases (F.P.-M., C.A., B.C.), Hospital Universitari i Politècnic La Fe, Valencia, Spain; Medical Department (D.P., N.M., R.G.-B., J.M.), Roche Farma S.A., Madrid, Spain; Neurology Department (A.G.-M.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Neurology Department (F.G.-G.), Hospital Clínico Universitario de Valencia, Valencia, Spain; Multiple Sclerosis and Neuroregeneration Research Group (J.C.-V., L.C., S.G.-P.), Institut d'Investigació Sanitària La Fe, Valencia, Spain; and Dynamic Science S.L. (E.Á.-G.), Madrid, Spain. fcomiralles@comv.es.ORCID 0000-0003-3767-3738
Daniel PrefasiFrom the Neuroimmunology Unit-National Referral Center for Demyelinating Diseases (F.P.-M., C.A., B.C.), Hospital Universitari i Politècnic La Fe, Valencia, Spain; Medical Department (D.P., N.M., R.G.-B., J.M.), Roche Farma S.A., Madrid, Spain; Neurology Department (A.G.-M.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Neurology Department (F.G.-G.), Hospital Clínico Universitario de Valencia, Valencia, Spain; Multiple Sclerosis and Neuroregeneration Research Group (J.C.-V., L.C., S.G.-P.), Institut d'Investigació Sanitària La Fe, Valencia, Spain; and Dynamic Science S.L. (E.Á.-G.), Madrid, Spain.
Antonio García-MerinoFrom the Neuroimmunology Unit-National Referral Center for Demyelinating Diseases (F.P.-M., C.A., B.C.), Hospital Universitari i Politècnic La Fe, Valencia, Spain; Medical Department (D.P., N.M., R.G.-B., J.M.), Roche Farma S.A., Madrid, Spain; Neurology Department (A.G.-M.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Neurology Department (F.G.-G.), Hospital Clínico Universitario de Valencia, Valencia, Spain; Multiple Sclerosis and Neuroregeneration Research Group (J.C.-V., L.C., S.G.-P.), Institut d'Investigació Sanitària La Fe, Valencia, Spain; and Dynamic Science S.L. (E.Á.-G.), Madrid, Spain.
Francisco Gascón-GiménezFrom the Neuroimmunology Unit-National Referral Center for Demyelinating Diseases (F.P.-M., C.A., B.C.), Hospital Universitari i Politècnic La Fe, Valencia, Spain; Medical Department (D.P., N.M., R.G.-B., J.M.), Roche Farma S.A., Madrid, Spain; Neurology Department (A.G.-M.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Neurology Department (F.G.-G.), Hospital Clínico Universitario de Valencia, Valencia, Spain; Multiple Sclerosis and Neuroregeneration Research Group (J.C.-V., L.C., S.G.-P.), Institut d'Investigació Sanitària La Fe, Valencia, Spain; and Dynamic Science S.L. (E.Á.-G.), Madrid, Spain.
Nicolás MedranoFrom the Neuroimmunology Unit-National Referral Center for Demyelinating Diseases (F.P.-M., C.A., B.C.), Hospital Universitari i Politècnic La Fe, Valencia, Spain; Medical Department (D.P., N.M., R.G.-B., J.M.), Roche Farma S.A., Madrid, Spain; Neurology Department (A.G.-M.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Neurology Department (F.G.-G.), Hospital Clínico Universitario de Valencia, Valencia, Spain; Multiple Sclerosis and Neuroregeneration Research Group (J.C.-V., L.C., S.G.-P.), Institut d'Investigació Sanitària La Fe, Valencia, Spain; and Dynamic Science S.L. (E.Á.-G.), Madrid, Spain.
Jessica Castillo-VillalbaFrom the Neuroimmunology Unit-National Referral Center for Demyelinating Diseases (F.P.-M., C.A., B.C.), Hospital Universitari i Politècnic La Fe, Valencia, Spain; Medical Department (D.P., N.M., R.G.-B., J.M.), Roche Farma S.A., Madrid, Spain; Neurology Department (A.G.-M.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Neurology Department (F.G.-G.), Hospital Clínico Universitario de Valencia, Valencia, Spain; Multiple Sclerosis and Neuroregeneration Research Group (J.C.-V., L.C., S.G.-P.), Institut d'Investigació Sanitària La Fe, Valencia, Spain; and Dynamic Science S.L. (E.Á.-G.), Madrid, Spain.
Laura CubasFrom the Neuroimmunology Unit-National Referral Center for Demyelinating Diseases (F.P.-M., C.A., B.C.), Hospital Universitari i Politècnic La Fe, Valencia, Spain; Medical Department (D.P., N.M., R.G.-B., J.M.), Roche Farma S.A., Madrid, Spain; Neurology Department (A.G.-M.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Neurology Department (F.G.-G.), Hospital Clínico Universitario de Valencia, Valencia, Spain; Multiple Sclerosis and Neuroregeneration Research Group (J.C.-V., L.C., S.G.-P.), Institut d'Investigació Sanitària La Fe, Valencia, Spain; and Dynamic Science S.L. (E.Á.-G.), Madrid, Spain.
Carmen AlcaláFrom the Neuroimmunology Unit-National Referral Center for Demyelinating Diseases (F.P.-M., C.A., B.C.), Hospital Universitari i Politècnic La Fe, Valencia, Spain; Medical Department (D.P., N.M., R.G.-B., J.M.), Roche Farma S.A., Madrid, Spain; Neurology Department (A.G.-M.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Neurology Department (F.G.-G.), Hospital Clínico Universitario de Valencia, Valencia, Spain; Multiple Sclerosis and Neuroregeneration Research Group (J.C.-V., L.C., S.G.-P.), Institut d'Investigació Sanitària La Fe, Valencia, Spain; and Dynamic Science S.L. (E.Á.-G.), Madrid, Spain.
Sara Gil-PerotínFrom the Neuroimmunology Unit-National Referral Center for Demyelinating Diseases (F.P.-M., C.A., B.C.), Hospital Universitari i Politècnic La Fe, Valencia, Spain; Medical Department (D.P., N.M., R.G.-B., J.M.), Roche Farma S.A., Madrid, Spain; Neurology Department (A.G.-M.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Neurology Department (F.G.-G.), Hospital Clínico Universitario de Valencia, Valencia, Spain; Multiple Sclerosis and Neuroregeneration Research Group (J.C.-V., L.C., S.G.-P.), Institut d'Investigació Sanitària La Fe, Valencia, Spain; and Dynamic Science S.L. (E.Á.-G.), Madrid, Spain.ORCID 0000-0003-3793-0116
Rocío Gómez-BallesterosFrom the Neuroimmunology Unit-National Referral Center for Demyelinating Diseases (F.P.-M., C.A., B.C.), Hospital Universitari i Politècnic La Fe, Valencia, Spain; Medical Department (D.P., N.M., R.G.-B., J.M.), Roche Farma S.A., Madrid, Spain; Neurology Department (A.G.-M.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Neurology Department (F.G.-G.), Hospital Clínico Universitario de Valencia, Valencia, Spain; Multiple Sclerosis and Neuroregeneration Research Group (J.C.-V., L.C., S.G.-P.), Institut d'Investigació Sanitària La Fe, Valencia, Spain; and Dynamic Science S.L. (E.Á.-G.), Madrid, Spain.
Jorge MaurinoFrom the Neuroimmunology Unit-National Referral Center for Demyelinating Diseases (F.P.-M., C.A., B.C.), Hospital Universitari i Politècnic La Fe, Valencia, Spain; Medical Department (D.P., N.M., R.G.-B., J.M.), Roche Farma S.A., Madrid, Spain; Neurology Department (A.G.-M.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Neurology Department (F.G.-G.), Hospital Clínico Universitario de Valencia, Valencia, Spain; Multiple Sclerosis and Neuroregeneration Research Group (J.C.-V., L.C., S.G.-P.), Institut d'Investigació Sanitària La Fe, Valencia, Spain; and Dynamic Science S.L. (E.Á.-G.), Madrid, Spain.
Esther Álvarez-GarcíaFrom the Neuroimmunology Unit-National Referral Center for Demyelinating Diseases (F.P.-M., C.A., B.C.), Hospital Universitari i Politècnic La Fe, Valencia, Spain; Medical Department (D.P., N.M., R.G.-B., J.M.), Roche Farma S.A., Madrid, Spain; Neurology Department (A.G.-M.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Neurology Department (F.G.-G.), Hospital Clínico Universitario de Valencia, Valencia, Spain; Multiple Sclerosis and Neuroregeneration Research Group (J.C.-V., L.C., S.G.-P.), Institut d'Investigació Sanitària La Fe, Valencia, Spain; and Dynamic Science S.L. (E.Á.-G.), Madrid, Spain.
Bonaventura CasanovaFrom the Neuroimmunology Unit-National Referral Center for Demyelinating Diseases (F.P.-M., C.A., B.C.), Hospital Universitari i Politècnic La Fe, Valencia, Spain; Medical Department (D.P., N.M., R.G.-B., J.M.), Roche Farma S.A., Madrid, Spain; Neurology Department (A.G.-M.), Hospital Universitario Puerta de Hierro, Madrid, Spain; Neurology Department (F.G.-G.), Hospital Clínico Universitario de Valencia, Valencia, Spain; Multiple Sclerosis and Neuroregeneration Research Group (J.C.-V., L.C., S.G.-P.), Institut d'Investigació Sanitària La Fe, Valencia, Spain; and Dynamic Science S.L. (E.Á.-G.), Madrid, Spain.
Hospital Universitari i Politècnic La Fe · ES
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the role of CSF chitinase 3-like-1 (CHI3L1), chitinase 3-like-2 (CHI3L2), and neurofilament light chain (NfL) in predicting the course of primary progressive MS (PPMS).
methodsWe analyzed CSF CHI3L1, CHI3L2, and NfL levels in 25 patients with PPMS with disease duration ≤10 years and no disease-modifying therapy for ≥6 months from the prospective Understanding Primary Progressive Multiple Sclerosis cohort study. CSF samples taken at disease diagnosis were analyzed using commercial ELISAs and following the manufacturer's instructions. Data on Expanded Disability Status Scale (EDSS) scores, disability progression, and cognitive function according to the Brief Repeatable Neuropsychological Battery were also assessed throughout the 1-year study follow-up.
resultsIncreasing CHI3L1 levels correlated with higher EDSS scores at baseline (ρ = 0.490, 95% CI 0.118-0.742,
conclusionsThis analysis supports the association between CSF CHI3L1 levels and neurologic disability according to EDSS scores in patients with PPMS. Other chitinase-like proteins such as CHI3L2 may also be involved. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that CSF CHI3L1 is associated with neurologic disability in patients with PPMS.
Indexed as
Disease ProgressionAgedChitinase-3-Like Protein 1ChitinasesFemaleFollow-Up StudiesHumansMaleMiddle AgedMultiple Sclerosis, Chronic ProgressiveNeurofilament ProteinsSeverity of Illness IndexCHI3L1 protein, humanCHI3L2 protein, humanChitinase-3-Like Protein 1Chitinasesneurofilament protein LNeurofilament Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.